Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy

Allison N. Duross, Megan J. Neufeld, Madeleine R. Landry, Justin G. Rosch, Colin T. Eaton, Gaurav Sahay, Charles Thomas, Conroy Sun

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Chemoradiation is an effective combined modality therapeutic approach that utilizes principles of spatial cooperation to combat the adaptability associated with cancer and to potentially expand the therapeutic window. Optimal therapeutic efficacy requires intelligent selection and refinement of radiosynergistic pharmaceutical agents, enhanced delivery methods, and temporal consideration. Here, a monodisperse sub-20 nm mixed poloxamer micelle (MPM) system was developed to deliver hydrophobic drugs intravenously, in tandem with ionizing radiation. This report demonstrates in vitro synergy and enhanced radiosensitivity when two molecularly targeted DNA repair inhibitors, talazoparib and buparlisib, are encapsulated and combined with radiation in a 4T1 murine breast cancer model. Evaluation of in vivo biodistribution and toxicity exhibited no reduction in particle accumulation upon radiation and a lack of both acute and chronic toxicities. In vivo efficacy studies suggested the promise of combining talazoparib, buparlisib, and radiation to enhance survival and control tumor growth. Tissue analysis suggests enhanced DNA damage leading to apoptosis, thus increasing efficacy. These findings highlight the challenges associated with utilizing clinically relevant inclusion criteria and treatment protocols because complete tumor regression and extended survival were masked by an aggressively metastasizing model. As with clinical treatment regimens, the findings here establish a need for further optimization of this multimodal platform.

Original languageEnglish (US)
Pages (from-to)12342-12356
Number of pages15
JournalACS Applied Materials and Interfaces
Volume11
Issue number13
DOIs
StatePublished - Apr 3 2019

Fingerprint

Chemoradiotherapy
DNA
Radiation
Toxicity
Tumors
Poloxamer
Ionizing radiation
Micelles
Cell death
Pharmaceutical Preparations
Drug products
Repair
Tissue
Apoptosis
NVP-BKM120
talazoparib

Keywords

  • Chemoradiotherapy
  • Combination Therapy
  • PARP
  • PI3K
  • Radiation
  • Synergy

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Duross, A. N., Neufeld, M. J., Landry, M. R., Rosch, J. G., Eaton, C. T., Sahay, G., ... Sun, C. (2019). Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. ACS Applied Materials and Interfaces, 11(13), 12342-12356. https://doi.org/10.1021/acsami.9b02408

Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. / Duross, Allison N.; Neufeld, Megan J.; Landry, Madeleine R.; Rosch, Justin G.; Eaton, Colin T.; Sahay, Gaurav; Thomas, Charles; Sun, Conroy.

In: ACS Applied Materials and Interfaces, Vol. 11, No. 13, 03.04.2019, p. 12342-12356.

Research output: Contribution to journalArticle

Duross, Allison N. ; Neufeld, Megan J. ; Landry, Madeleine R. ; Rosch, Justin G. ; Eaton, Colin T. ; Sahay, Gaurav ; Thomas, Charles ; Sun, Conroy. / Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy. In: ACS Applied Materials and Interfaces. 2019 ; Vol. 11, No. 13. pp. 12342-12356.
@article{0df3f1a7bb4b494196ad0af4238e11e7,
title = "Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy",
abstract = "Chemoradiation is an effective combined modality therapeutic approach that utilizes principles of spatial cooperation to combat the adaptability associated with cancer and to potentially expand the therapeutic window. Optimal therapeutic efficacy requires intelligent selection and refinement of radiosynergistic pharmaceutical agents, enhanced delivery methods, and temporal consideration. Here, a monodisperse sub-20 nm mixed poloxamer micelle (MPM) system was developed to deliver hydrophobic drugs intravenously, in tandem with ionizing radiation. This report demonstrates in vitro synergy and enhanced radiosensitivity when two molecularly targeted DNA repair inhibitors, talazoparib and buparlisib, are encapsulated and combined with radiation in a 4T1 murine breast cancer model. Evaluation of in vivo biodistribution and toxicity exhibited no reduction in particle accumulation upon radiation and a lack of both acute and chronic toxicities. In vivo efficacy studies suggested the promise of combining talazoparib, buparlisib, and radiation to enhance survival and control tumor growth. Tissue analysis suggests enhanced DNA damage leading to apoptosis, thus increasing efficacy. These findings highlight the challenges associated with utilizing clinically relevant inclusion criteria and treatment protocols because complete tumor regression and extended survival were masked by an aggressively metastasizing model. As with clinical treatment regimens, the findings here establish a need for further optimization of this multimodal platform.",
keywords = "Chemoradiotherapy, Combination Therapy, PARP, PI3K, Radiation, Synergy",
author = "Duross, {Allison N.} and Neufeld, {Megan J.} and Landry, {Madeleine R.} and Rosch, {Justin G.} and Eaton, {Colin T.} and Gaurav Sahay and Charles Thomas and Conroy Sun",
year = "2019",
month = "4",
day = "3",
doi = "10.1021/acsami.9b02408",
language = "English (US)",
volume = "11",
pages = "12342--12356",
journal = "ACS applied materials & interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "13",

}

TY - JOUR

T1 - Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy

AU - Duross, Allison N.

AU - Neufeld, Megan J.

AU - Landry, Madeleine R.

AU - Rosch, Justin G.

AU - Eaton, Colin T.

AU - Sahay, Gaurav

AU - Thomas, Charles

AU - Sun, Conroy

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Chemoradiation is an effective combined modality therapeutic approach that utilizes principles of spatial cooperation to combat the adaptability associated with cancer and to potentially expand the therapeutic window. Optimal therapeutic efficacy requires intelligent selection and refinement of radiosynergistic pharmaceutical agents, enhanced delivery methods, and temporal consideration. Here, a monodisperse sub-20 nm mixed poloxamer micelle (MPM) system was developed to deliver hydrophobic drugs intravenously, in tandem with ionizing radiation. This report demonstrates in vitro synergy and enhanced radiosensitivity when two molecularly targeted DNA repair inhibitors, talazoparib and buparlisib, are encapsulated and combined with radiation in a 4T1 murine breast cancer model. Evaluation of in vivo biodistribution and toxicity exhibited no reduction in particle accumulation upon radiation and a lack of both acute and chronic toxicities. In vivo efficacy studies suggested the promise of combining talazoparib, buparlisib, and radiation to enhance survival and control tumor growth. Tissue analysis suggests enhanced DNA damage leading to apoptosis, thus increasing efficacy. These findings highlight the challenges associated with utilizing clinically relevant inclusion criteria and treatment protocols because complete tumor regression and extended survival were masked by an aggressively metastasizing model. As with clinical treatment regimens, the findings here establish a need for further optimization of this multimodal platform.

AB - Chemoradiation is an effective combined modality therapeutic approach that utilizes principles of spatial cooperation to combat the adaptability associated with cancer and to potentially expand the therapeutic window. Optimal therapeutic efficacy requires intelligent selection and refinement of radiosynergistic pharmaceutical agents, enhanced delivery methods, and temporal consideration. Here, a monodisperse sub-20 nm mixed poloxamer micelle (MPM) system was developed to deliver hydrophobic drugs intravenously, in tandem with ionizing radiation. This report demonstrates in vitro synergy and enhanced radiosensitivity when two molecularly targeted DNA repair inhibitors, talazoparib and buparlisib, are encapsulated and combined with radiation in a 4T1 murine breast cancer model. Evaluation of in vivo biodistribution and toxicity exhibited no reduction in particle accumulation upon radiation and a lack of both acute and chronic toxicities. In vivo efficacy studies suggested the promise of combining talazoparib, buparlisib, and radiation to enhance survival and control tumor growth. Tissue analysis suggests enhanced DNA damage leading to apoptosis, thus increasing efficacy. These findings highlight the challenges associated with utilizing clinically relevant inclusion criteria and treatment protocols because complete tumor regression and extended survival were masked by an aggressively metastasizing model. As with clinical treatment regimens, the findings here establish a need for further optimization of this multimodal platform.

KW - Chemoradiotherapy

KW - Combination Therapy

KW - PARP

KW - PI3K

KW - Radiation

KW - Synergy

UR - http://www.scopus.com/inward/record.url?scp=85063388983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063388983&partnerID=8YFLogxK

U2 - 10.1021/acsami.9b02408

DO - 10.1021/acsami.9b02408

M3 - Article

C2 - 30860347

AN - SCOPUS:85063388983

VL - 11

SP - 12342

EP - 12356

JO - ACS applied materials & interfaces

JF - ACS applied materials & interfaces

SN - 1944-8244

IS - 13

ER -